←Back to list

Graph AI

AI-native operating system for pharmacovigilance and patient safety
Graph AI builds AI-native software for pharmacovigilance and patient safety teams at pharmaceutical and biotech companies, sold as Graph Safety. Its modules cover adverse-event intake and triage, automated case processing on an intelligent safety database, aggregate regulatory reporting, and signal detection. The company reports cutting case-processing turnaround from more than three hours to under 10 minutes and lowering operating costs by up to 66%, with enterprise customers monitoring more than 300 drugs. Founded in 2024 by Raghav Parvataraju (CEO), Vijay Ponukumati (CTO), Mohan Konyala (CPO) and Ashutosh Bordekar (CFO), a team drawn from Infosys, Google, ServiceNow, LTIMindtree and Wipro. The business began as an AI services firm built around an in-house agentic platform and pivoted to SaaS after seeing a rival IT services implementation fail over 18 months at a life sciences customer.
Enterprise Systems (Healthcare) 📍 Pleasanton, CA Founded 2024
Current Valuation
Private
PRIVATE

IPO Outlookprivate

Is Graph AI going public?
No. Graph AI is private and has not filed to go public. There is no S-1 on file.
What is Graph AI's valuation in 2026?
No confirmed valuation is on record for Graph AI. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Graph AI filed an S-1?
No public S-1 is on file for Graph AI.
Who are Graph AI's investors?
Graph AI's investors include Insight Partners, Bessemer Venture Partners.
How much has Graph AI raised?
Graph AI has raised $16.3M in total across 2 disclosed rounds, most recently a Series A of $13.3M in Sep 2026.
Is Graph AI publicly traded — can you buy Graph AI stock?
No. Graph AI is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Graph AI on its Pre-IPO Access Desk.
How to actually get exposure to Graph AI →
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.

Company Profile

CEO
Raghav Parvataraju
Founded
2024
HQ
Pleasanton, CA
Total Raised
$16.3M
Last Round
Series A — $13.3M (Sep 2026) · Lead: Insight Partners
IPO Status
private

Fundraising Status

Series A · $13.3M · 1 mo ago
privateTotal raised $16.3M2 disclosed rounds

Growth & Valuation

Capital raised per round
Capital raised per funding round$3MSeed$13MSeries A
Charts built from publicly disclosed funding rounds and revenue estimates. Approximate, not real-time, not investment advice.

Funding History

RoundAmountDateLead InvestorPost-Money
Series A$13.3MSep 2026Insight Partners—
Seed$3MOct 2025Bessemer Venture Partners—

Talent Signal

Hiring trend
▶ Hiring steady
0% vs 2026-09
Open roles
20
via careers page
Product-build share
35%
engineering, research, product, design
Trajectory
steady
balanced build + GTM — 35% builders vs 65% go-to-market/G&A — scaling both sides.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by month20Sep '2620Oct '26
Open roles by function
Open roles by functionMarketing4Ops & People4Engineering4Support4Design2Security1Sales & GTM1
■ product-building   ■ go-to-market / G&A
Associate Product Support Engineer (L1)Full-stack DeveloperInfrastructure & Enterprise Applications EngineerSupport audits, compliance requirements, security operations, and incident invesDesign and validate statistical signal-detection methods powering the /signal moQuality Assurance Engineer
Counted from Graph AI's live job board as of 2026-10-11; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.

Founders & Key People

Raghav ParvatarajuVijay PonukumatiMohan KonyalaAshutosh Bordekar

Investors

Insight Partners · Bessemer Venture Partners

Products

  • /intake - captures and triages incoming adverse-event reports across all channels
  • /nucleus - intelligent safety database that automates case processing end to end
  • /report - automated aggregate safety reporting (launching September 2026)
  • /signal - emerging safety signal and pattern detection (design partnerships secured, launching later)

Competitors

Veeva Systems · ArisGlobal · Oracle Health Sciences · IQVIA · Certara
AIPharmacovigilanceDrug SafetyLife SciencesEnterprise Software
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.